1. www.ehnheart.org
2. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ: Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367:1747-1757, 2006
3. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, Op Reimer WS, Weissberg P, Wood D, Yarnell J, Zamorano JL, Walma E, Fitzgerald T, Cooney MT, Dudina A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Funck-Brentano C, Filippatos G, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Altiner A, Bonora E, Durrington PN, Fagard R, Giampaoli S, Hemingway H, Hakansson J, Kjeldsen SE, Larsen L, Mancia G, Manolis AJ, Orth-Gomer K, Pedersen T, Rayner M, Ryden L, Sammut M, Schneiderman N, Stalenhoef AF, Tokgozoglu L, Wiklund O, Zampelas A:
European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 14 Suppl 2:S1-113, 2007
4. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364:937-952, 2004
5. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, Malmberg K: Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 359:2140-2144, 2002
6. Bartnik M, Ryden L, Ferrari R, Malmberg K, Pyorala K, Simoons M, Standl E, Soler-Soler J, Ohrvik J: The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 25:1880-1890, 2004
7. Hu DY, Pan CY, Yu JM: The relationship between coronary artery disease and abnormal glucose regulation in China: the China Heart Survey. Eur Heart J 27:2573-2579, 2006
8. Johansen OE, Birkeland KI, Brustad E, Aaser E, Lindahl AK, Midha R, Ueland T, Aukrust P, Gullestad L: Undiagnosed dysglycaemia and inflammation in cardiovascular disease. Eur J Clin Invest 36:544-551, 2006
9. Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, Cameron AJ, Dwyer T, Taylor HR, Tonkin AM, Wong TY, McNeil J, Shaw JE: Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 116:151-157, 2007
10. Norhammar A, Lindback J, Ryden L, Wallentin L, Stenestrand U: Improved but still high short- and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: a time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission. Heart 93:1577-1583, 2007
11. Lenzen M, Ryden L, Ohrvik J, Bartnik M, Malmberg K, Scholte Op Reimer W, Simoons ML: Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. Eur Heart J 27:2969-2974, 2006
12. Bartnik M, Malmberg K, Hamsten A, Efendic S, Norhammar A, Silveira A, Tenerz A, Ohrvik J, Ryden L: Abnormal glucose tolerance--a common risk factor in patients with acute myocardial infarction in comparison with population-based controls. J Intern Med 256:288-297, 2004
13. Wilhelmsen L, Welin L, Svardsudd K, Wedel H, Eriksson H, Hansson PO, Rosengren A:
Secular changes in cardiovascular risk factors and attack rate of myocardial infarction among men aged 50 in Gothenburg, Sweden. Accurate prediction using risk models. J Intern Med 263:636-643, 2008
14. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, Fox KA, Hasdai D, Ohman EM, Wallentin L, Wijns W: Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28:1598-1660, 2007 15. Lusis AJ: Atherosclerosis. Nature 407:233-241, 2000
16. Libby P, Ridker PM, Hansson GK: Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 54:2129-2138, 2009
17. Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, Kiowski W, Luscher TF, Mancia G, Natali A, Oliver JJ, Pessina AC, Rizzoni D, Rossi GP, Salvetti A, Spieker LE, Taddei S, Webb DJ: Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 23:233-246, 2005 18. Tesfamariam B, Brown ML, Cohen RA: Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J Clin Invest 87:1643-1648, 1991
19. Williams SB, Goldfine AB, Timimi FK, Ting HH, Roddy MA, Simonson DC, Creager MA: Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo.
Circulation 97:1695-1701, 1998
20. Rask-Madsen C, King GL: Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab 3:46-56, 2007
21. www.eatlas.idf.org
22. Shaw JE, Sicree RA, Zimmet PZ: Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87:4-14, 2010
23. Kannel WB, McGee DL: Diabetes and cardiovascular disease. The Framingham study.
Jama 241:2035-2038, 1979
24. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998
25. Hu G, Jousilahti P, Qiao Q, Katoh S, Tuomilehto J: Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction. Diabetologia 48:856-861, 2005
26. Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC, Speizer FE, Nathan DM, Manson JE: The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med 161:1717-1723, 2001
27. Malmberg K, Ryden L: Myocardial infarction in patients with diabetes mellitus. Eur Heart J 9:259-264, 1988
28. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 26:688-696, 2003
29. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H: Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 44 Suppl 2:S14-21, 2001
30. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ: Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159:1160-1167, 2004
31. Larsson SC, Orsini N, Wolk A: Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97:1679-1687, 2005
32. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M: Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92:2076-2083, 2005 33. Larsson SC, Mantzoros CS, Wolk A: Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 121:856-862, 2007
34. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. Geneva, World Health Org., 2006
35. World Health Organization Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation.Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva World Health Org., 1999
36. Standards of medical care in diabetes--2010. Diabetes Care 33 Suppl 1:S11-61, 2010 37. Coutinho M, Gerstein HC, Wang Y, Yusuf S: The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22:233-240, 1999
38. Levitan EB, Song Y, Ford ES, Liu S: Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 164:2147-2155, 2004
39. Elley CR, Kenealy T, Robinson E, Drury PL: Glycated haemoglobin and cardiovascular outcomes in people with Type 2 diabetes: a large prospective cohort study. Diabet Med 25:1295-1301, 2008
40. Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, Cosentino F, Jonsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL, Deckers JW, Bertrand M, Charbonnel B, Erdmann E, Ferrannini E, Flyvbjerg A, Gohlke H, Juanatey JR, Graham I, Monteiro PF, Parhofer K, Pyorala K, Raz I, Schernthaner G, Volpe M, Wood D: Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28:88-136, 2007
41. Laakso M, Kuusisto J: Understanding patient needs: Diabetology for cardiologists Eur Heart J Suppl 5:B5-B13 2003
42. Stumvoll M, Goldstein BJ, van Haeften TW: Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365:1333-1346, 2005
43. Kawahito S, Kitahata H, Oshita S: Problems associated with glucose toxicity: role of hyperglycemia-induced oxidative stress. World J Gastroenterol 15:4137-4142, 2009
44. Nigro J, Osman N, Dart AM, Little PJ: Insulin resistance and atherosclerosis. Endocr Rev 27:242-259, 2006
45. Rask-Madsen C, King GL: Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. Arterioscler Thromb Vasc Biol 25:487-496, 2005
46. Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, Da Ros R, Motz E:
Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 106:1211-1218, 2002
47. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820, 2001
48. Brownlee M: The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615-1625, 2005
49. Kim JA, Montagnani M, Koh KK, Quon MJ: Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms.
Circulation 113:1888-1904, 2006
50. Beckman JA, Goldfine AB, Gordon MB, Garrett LA, Creager MA: Inhibition of protein kinase Cbeta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ Res 90:107-111, 2002
51. Pickup JC: Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27:813-823, 2004
52. Clement S, Braithwaite SS, Magee MF, Ahmann A, Smith EP, Schafer RG, Hirsch IB:
Management of diabetes and hyperglycemia in hospitals. Diabetes Care 27:553-591, 2004 53. Opie LH: Metabolic management of acute myocardial infarction comes to the fore and extends beyond control of hyperglycemia. Circulation 117:2172-2177, 2008
54. Capes SE, Hunt D, Malmberg K, Gerstein HC: Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview.
Lancet 355:773-778, 2000
55. Norhammar AM, Ryden L, Malmberg K: Admission plasma glucose. Independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients. Diabetes Care 22:1827-1831, 1999
56. Kosiborod M, Rathore SS, Inzucchi SE, Masoudi FA, Wang Y, Havranek EP, Krumholz HM: Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation 111:3078-3086, 2005
57. Pinto DS, Skolnick AH, Kirtane AJ, Murphy SA, Barron HV, Giugliano RP, Cannon CP, Braunwald E, Gibson CM: U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 46:178-180, 2005
58. Svensson AM, McGuire DK, Abrahamsson P, Dellborg M: Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J 26:1255-1261, 2005
59. Goyal A, Mahaffey KW, Garg J, Nicolau JC, Hochman JS, Weaver WD, Theroux P, Oliveira
GB, Todaro TG, Mojcik CF, Armstrong PW, Granger CB: Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study. Eur Heart J 27:1289-1297, 2006
60. Sinnaeve PR, Steg PG, Fox KA, Van de Werf F, Montalescot G, Granger CB, Knobel E, Anderson FA, Dabbous OH, Avezum A: Association of elevated fasting glucose with increased short-term and 6-month mortality in ST-segment elevation and non-ST-segment elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. Arch Intern Med 169:402-409, 2009
61. Pinto DS, Kirtane AJ, Pride YB, Murphy SA, Sabatine MS, Cannon CP, Gibson CM:
Association of blood glucose with angiographic and clinical outcomes among patients with ST-segment elevation myocardial infarction (from the CLARITY-TIMI-28 study). Am J Cardiol 101:303-307, 2008
62. Ishihara M, Kagawa E, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, Nakama Y, Maruhashi T, Ookawa K, Dai K, Aokage Y: Impact of admission hyperglycemia and diabetes mellitus on short- and long-term mortality after acute myocardial infarction in the coronary intervention era. Am J Cardiol 99:1674-1679, 2007
63. Goyal A, Mehta SR, Diaz R, Gerstein HC, Afzal R, Xavier D, Liu L, Pais P, Yusuf S:
Differential clinical outcomes associated with hypoglycemia and hyperglycemia in acute myocardial infarction. Circulation 120:2429-2437, 2009
64. Vetter NJ, Strange RC, Adams W, Oliver MF: Initial metabolic and hormonal response to acute myocardial infarction. Lancet 1:284-288, 1974
65. Wallander M, Malmberg K, Norhammar A, Ryden L, Tenerz A: Oral glucose tolerance test:
a reliable tool for early detection of glucose abnormalities in patients with acute myocardial infarction in clinical practice: a report on repeated oral glucose tolerance tests from the GAMI study. Diabetes Care 31:36-38, 2008
66. Deedwania P, Kosiborod M, Barrett E, Ceriello A, Isley W, Mazzone T, Raskin P:
Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism.
Circulation 117:1610-1619, 2008
67. Sodi-Pallares D, Testelli MR, Fishleder BL, Bisteni A, Medrano GA, Friedland C, De Micheli A: Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report. Am J Cardiol 9:166-181, 1962
68. Ceremuzynski L, Budaj A, Czepiel A, Burzykowski T, Achremczyk P, Smielak-Korombel W, Maciejewicz J, Dziubinska J, Nartowicz E, Kawka-Urbanek T, Piotrowski W, Hanzlik J, Cieslinski A, Kawecka-Jaszcz K, Gessek J, Wrabec K: Low-dose glucose-insulin-potassium is ineffective in acute myocardial infarction: results of a randomized multicenter Pol-GIK trial.
Cardiovasc Drugs Ther 13:191-200, 1999
69. Mehta SR, Yusuf S, Diaz R, Zhu J, Pais P, Xavier D, Paolasso E, Ahmed R, Xie C, Kazmi K, Tai J, Orlandini A, Pogue J, Liu L: Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. Jama 293:437-446, 2005
70. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, Wedel H, Welin L:
Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 26:57-65, 1995
71. Malmberg K: Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. Bmj 314:1512-1515, 1997
72. Malmberg K, Ryden L, Wedel H, Birkeland K, Bootsma A, Dickstein K, Efendic S, Fisher M, Hamsten A, Herlitz J, Hildebrandt P, MacLeod K, Laakso M, Torp-Pedersen C, Waldenstrom A: Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 26:650-661, 2005
73. Cheung NW, Wong VW, McLean M: The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care 29:765-770, 2006
74. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643-2653, 2005
75. UKPDS33: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837-853, 1998
76. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577-1589, 2008
77. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS: Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials:
a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 119:351-357, 2009
78. Ryden L, Malmberg K, Mellbin L: Is glucose normalization an evidence-based treatment for patients with type 2 diabetes mellitus? Nat Clin Pract Endocrinol Metab 5:8-9, 2009 79. UKPDS34: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:854-865, 1998
80. Meinert CL, Knatterud GL, Prout TE, Klimt CR: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results.
Diabetes 19:Suppl:789-830, 1970
81. Wikstrom G, Malmberg K, Ryden L: Improved knowledge of antidiabetic treatment--a necessity for the modern cardiologist. Eur Heart J 20:403-405, 1999
82. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. Jama 298:1180-1188, 2007
83. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457-2471, 2007
84. Nichols GA, Koro CE, Gullion CM, Ephross SA, Brown JB: The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev 21:51-57, 2005 85. Smooke S, Horwich TB, Fonarow GC: Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J 149:168-174, 2005
86. Johnsen SP, Monster TB, Olsen ML, Thisted H, McLaughlin JK, Sorensen HT, Lervang HH, Rungby J: Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs. Am J Ther 13:134-140, 2006
87. McGuire DK, Newby LK, Bhapkar MV, Moliterno DJ, Hochman JS, Klein WW, Weaver WD, Pfisterer M, Corbalan R, Dellborg M, Granger CB, Van De Werf F, Topol EJ, Califf RM:
Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. Am Heart J 147:246-252, 2004
88. Smith U, Gale EA: Does diabetes therapy influence the risk of cancer? Diabetologia 52:1699-1708, 2009
89. Barrett LK, Singer M, Clapp LH: Vasopressin: mechanisms of action on the vasculature in health and in septic shock. Crit Care Med 35:33-40, 2007
90. McAlpine HM, Morton JJ, Leckie B, Rumley A, Gillen G, Dargie HJ: Neuroendocrine activation after acute myocardial infarction. Br Heart J 60:117-124, 1988
91. Goldsmith SR: Treatment options for hyponatremia in heart failure. Heart Fail Rev 14:65-73, 2009
92. Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN: The neurohumoral axis in congestive heart failure. Ann Intern Med 101:370-377, 1984
93. Morgenthaler NG, Struck J, Alonso C, Bergmann A: Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52:112-119, 2006 94. Morgenthaler NG, Struck J, Jochberger S, Dunser MW: Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab 19:43-49, 2008
95. Khan SQ, Dhillon OS, O’Brien RJ, Struck J, Quinn PA, Morgenthaler NG, Squire IB, Davies JE, Bergmann A, Ng LL: C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 115:2103-2110, 2007
96. Voors AA, von Haehling S, Anker SD, Hillege HL, Struck J, Hartmann O, Bergmann A, Squire I, van Veldhuisen DJ, Dickstein K: C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J 30:1187-1194, 2009
97. Gegenhuber A, Struck J, Dieplinger B, Poelz W, Pacher R, Morgenthaler NG, Bergmann A, Haltmayer M, Mueller T: Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail 13:42-49, 2007 98. Neuhold S, Huelsmann M, Strunk G, Stoiser B, Struck J, Morgenthaler NG, Bergmann A, Moertl D, Berger R, Pacher R: Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol 52:266-272, 2008
99. Lee PD, Giudice LC, Conover CA, Powell DR: Insulin-like growth factor binding protein-1:
recent findings and new directions. Proc Soc Exp Biol Med 216:319-357, 1997
100. Wallander M, Norhammar A, Malmberg K, Ohrvik J, Ryden L, Brismar K: IGF binding protein 1 predicts cardiovascular morbidity and mortality in patients with acute myocardial infarction and type 2 diabetes. Diabetes Care 30:2343-2348, 2007
101. Janszky I, Hallqvist J, Ljung R, Hammar N: Insulin-like growth factor binding protein-1 is a long-term predictor of heart failure in survivors of a first acute myocardial infarction and population controls. Int J Cardiol, 2008
102. Mesotten D, Van den Berghe G: Changes within the GH/IGF-I/IGFBP axis in critical illness. Crit Care Clin 22:17-28, v, 2006
103. Catrina SB, Rotarus R, Botusan IR, Coculescu M, Brismar K: Desmopressin increases IGF-binding protein-1 in humans. Eur J Endocrinol 158:479-482, 2008
104. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836-843, 2000
105. Bjerre M, Hansen TK, Flyvbjerg A: Complement activation and cardiovascular disease.
Horm Metab Res 40:626-634, 2008
106. Fujita T: Evolution of the lectin-complement pathway and its role in innate immunity. Nat Rev Immunol 2:346-353, 2002
107. Garred P, Larsen F, Seyfarth J, Fujita R, Madsen HO: Mannose-binding lectin and its genetic variants. Genes Immun 7:85-94, 2006
108. Steffensen R, Thiel S, Varming K, Jersild C, Jensenius JC: Detection of structural gene mutations and promoter polymorphisms in the mannan-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers. J Immunol Methods 241:33-42, 2000
109. Ip WK, Takahashi K, Ezekowitz RA, Stuart LM: Mannose-binding lectin and innate immunity. Immunol Rev 230:9-21, 2009
110. Kawasaki T, Etoh R, Yamashina I: Isolation and characterization of a mannan-binding protein from rabbit liver. Biochem Biophys Res Commun 81:1018-1024, 1978
111. Super M, Thiel S, Lu J, Levinsky RJ, Turner MW: Association of low levels of mannan-binding protein with a common defect of opsonisation. Lancet 2:1236-1239, 1989
112. Hansen TK: Mannose-binding lectin (MBL) and vascular complications in diabetes. Horm Metab Res 37 Suppl 1:95-98, 2005
113. Thiel S, Frederiksen PD, Jensenius JC: Clinical manifestations of mannan-binding lectin deficiency. Mol Immunol 43:86-96, 2006
114. Busche MN, Walsh MC, McMullen ME, Guikema BJ, Stahl GL: Mannose-binding lectin plays a critical role in myocardial ischaemia and reperfusion injury in a mouse model of diabetes. Diabetologia 51:1544-1551, 2008
115. La Bonte L R, B D, G D-G, G S, P M: The mannose-binding lectin pathway is a significant contributor to reperfusion injury in the type 2 diabetic heart. Diab Vasc Dis Res 6:172 -180, 2009 116. Pesonen E, Hallman M, Sarna S, Andsberg E, Haataja R, Meri S, Persson K, Puolakkainen M, Ohlin H, Truedsson L: Mannose-binding lectin as a risk factor for acute coronary syndromes.
Ann Med:1-8, 2009
117. Hovind P, Hansen TK, Tarnow L, Thiel S, Steffensen R, Flyvbjerg A, Parving HH:
Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes: an inception cohort study. Diabetes 54:1523-1527, 2005
118. Hansen TK, Tarnow L, Thiel S, Steffensen R, Stehouwer CD, Schalkwijk CG, Parving HH, Flyvbjerg A: Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes 53:1570-1576, 2004
119. Madsen HO, Videm V, Svejgaard A, Svennevig JL, Garred P: Association of mannose-binding-lectin deficiency with severe atherosclerosis. Lancet 352:959-960, 1998
120. Hegele RA, Ban MR, Anderson CM, Spence JD: Infection-susceptibility alleles of mannose-binding lectin are associated with increased carotid plaque area. J Investig Med 48:198-202, 2000